{
  "@context": "https://schema.org/",
  "@type": "MedicalTherapy",
  "@id": "aku:vascular:genetic:eds-005-celiprolol",
  "name": "Celiprolol Evidence in Vascular Ehlers-Danlos Syndrome",
  "alternateName": ["Celiprolol Trial", "vEDS Medical Management"],
  "description": "Celiprolol is a third-generation beta-blocker with unique beta-2 agonist properties that has shown efficacy in reducing cardiovascular events in vascular Ehlers-Danlos syndrome. The landmark randomized controlled trial demonstrated significant reduction in arterial rupture and dissection. Celiprolol is now considered first-line medical therapy for vEDS, though the mechanism beyond standard beta-blockade remains incompletely understood. Availability varies by country.",
  "code": [
    {
      "@type": "MedicalCode",
      "codeValue": "Q79.63",
      "codingSystem": "ICD-10-CM",
      "name": "Vascular Ehlers-Danlos syndrome"
    },
    {
      "@type": "MedicalCode",
      "codeValue": "83470001",
      "codingSystem": "SNOMED-CT",
      "name": "Ehlers-Danlos syndrome type IV"
    }
  ],
  "classification": {
    "domain_path": "health-sciences/medicine/surgery/vascular/pathology/genetic-ctd",
    "type": "treatment",
    "subtype": "medical_management",
    "difficulty": "advanced",
    "importance": "critical",
    "board_yield": "HIGH",
    "aku_id": "EDS-005",
    "keywords": ["celiprolol", "beta-blocker", "vEDS treatment", "vascular protection", "clinical trial"],
    "medical_specialty": "vascular_surgery",
    "clinical_context": "connective_tissue_disorder"
  },
  "content": {
    "statement": {
      "text": "Celiprolol is a third-generation beta-blocker with beta-2 agonist properties that demonstrated 60% relative risk reduction in arterial events in vascular Ehlers-Danlos syndrome in the only randomized controlled trial for this condition.",
      "formal": "Celiprolol in vEDS: RCT Evidence → 60% Relative Risk Reduction in Arterial Events → Only Medication with RCT Evidence in vEDS"
    },
    "explanation": {
      "intuition": "While vEDS tissue cannot be fixed, celiprolol appears to reduce the stress on fragile blood vessels, cutting the rate of arterial disasters by more than half in the clinical trial.",
      "key_insight": "Celiprolol is the ONLY medication with randomized trial evidence in vEDS. The 2010 Ong trial showed dramatic benefit (20% vs 50% event rate), with a number needed to treat of 3-4 patients to prevent one arterial event.",
      "technical_details": "Celiprolol's unique beta-2 agonist activity causes vasodilation while beta-1 antagonism reduces heart rate and contractility. Dose is titrated to 200-400mg twice daily. Not FDA-approved in the US, requiring compassionate use or international pharmacy. If unavailable, conventional beta-blockers are used."
    }
  },
  "celiprolol_pharmacology": {
    "drug_class": "Third-generation beta-blocker",
    "unique_properties": {
      "beta_1_antagonist": "Reduces heart rate and contractility",
      "beta_2_agonist": "Causes vasodilation",
      "alpha_2_agonist": "Additional vasodilatory effect",
      "no_negative_inotropy": "Better cardiac output preservation"
    },
    "half_life": "5-7 hours",
    "dosing": {
      "starting": "100-200 mg twice daily",
      "target": "200-400 mg twice daily",
      "maximum": "400 mg twice daily"
    },
    "administration": "Take on empty stomach (food reduces absorption)"
  },
  "clinical_features": {
    "presentation": [
      "Known vEDS diagnosis",
      "Family history of vEDS arterial events",
      "Seeking primary prevention"
    ],
    "diagnosis": [
      "Confirmed COL3A1 mutation",
      "Clinical diagnosis per Villefranche criteria"
    ],
    "treatment": [
      "Celiprolol as primary prevention",
      "Dose titration over weeks",
      "Lifelong therapy"
    ]
  },
  "landmark_clinical_trial": {
    "study": "Ong et al., Lancet 2010",
    "design": {
      "type": "Open-label randomized controlled trial",
      "population": "vEDS patients with confirmed COL3A1 mutation",
      "n": "53 patients randomized",
      "intervention": "Celiprolol vs. no treatment",
      "follow_up": "Mean 47 months"
    },
    "results": {
      "primary_endpoint": {
        "definition": "Arterial rupture or dissection",
        "celiprolol_group": "20% event rate (5/25)",
        "control_group": "50% event rate (14/28)",
        "risk_reduction": "Relative risk reduction of 60%"
      },
      "hazard_ratio": "HR 0.36 (95% CI 0.15-0.88), p=0.040",
      "number_needed_to_treat": "3-4 to prevent one event"
    },
    "conclusion": "Significant reduction in arterial events with celiprolol"
  },
  "proposed_mechanisms": {
    "hemodynamic": {
      "reduced_dp_dt": "Decreased rate of pressure rise in systole",
      "reduced_heart_rate": "Less mechanical stress on vessels",
      "vasodilation": "Beta-2 agonism may reduce peripheral resistance"
    },
    "potential_matrix_effects": {
      "hypothesis": "May affect collagen synthesis or TGF-beta signaling",
      "evidence": "Limited - primarily hemodynamic mechanism assumed"
    },
    "uncertain": {
      "note": "Exact mechanism beyond beta-blockade unclear",
      "question": "Whether other beta-blockers would be equally effective"
    }
  },
  "clinical_application": {
    "who_should_receive": {
      "indication": "All vEDS patients with confirmed COL3A1 mutation",
      "timing": "Start at diagnosis",
      "age": "Can be used in children (dose adjusted)"
    },
    "target_parameters": {
      "heart_rate": "<70 bpm at rest",
      "blood_pressure": "Low-normal (but avoid hypotension)"
    },
    "titration": {
      "start_low": "100-200 mg daily",
      "increase": "Gradually to 200 mg twice daily or maximum tolerated"
    }
  },
  "availability_and_access": {
    "europe": "Available in many European countries",
    "united_states": {
      "status": "Not FDA-approved",
      "access": "Compassionate use, patient assistance programs, international pharmacy"
    },
    "alternatives_if_unavailable": {
      "other_beta_blockers": "Atenolol, metoprolol, propranolol",
      "rationale": "Theoretical benefit from hemodynamic effects",
      "evidence": "Less evidence than celiprolol specifically"
    }
  },
  "contraindications_and_cautions": {
    "contraindications": [
      "Severe asthma (beta-2 agonism may help, but caution)",
      "Severe bradycardia",
      "Decompensated heart failure",
      "Known hypersensitivity"
    ],
    "cautions": [
      "Hypotension (vasodilatory effects)",
      "Peripheral arterial disease (though vasodilation may help)"
    ],
    "pregnancy": {
      "consideration": "Limited data, discuss risks and benefits",
      "general": "Beta-blockers generally considered safe in pregnancy"
    }
  },
  "side_effects": {
    "common": [
      "Fatigue",
      "Headache",
      "Dizziness",
      "Cold extremities (less than other beta-blockers due to beta-2 agonism)"
    ],
    "less_common": [
      "Bradycardia",
      "Hypotension",
      "GI disturbance"
    ],
    "advantage_over_other_beta_blockers": "Beta-2 agonism may reduce peripheral symptoms"
  },
  "monitoring": {
    "baseline": [
      "Heart rate and blood pressure",
      "ECG (assess for conduction abnormalities)"
    ],
    "ongoing": [
      "Heart rate and blood pressure at each visit",
      "Symptom assessment"
    ]
  },
  "ongoing_research": {
    "questions": [
      "Is celiprolol specifically better than other beta-blockers?",
      "What is the optimal dose?",
      "Are there molecular effects beyond hemodynamics?",
      "Efficacy in pediatric population?"
    ],
    "observational_data": "Continued follow-up supports long-term benefit"
  },
  "comparison_with_marfan_treatment": {
    "marfan": {
      "agents": "Atenolol, propranolol, metoprolol, losartan",
      "mechanism": "Hemodynamic + TGF-beta modulation (ARBs)"
    },
    "veds": {
      "agents": "Celiprolol (preferred) or other beta-blockers",
      "arbs": "Not established in vEDS"
    },
    "difference": "ARBs have evidence in Marfan but not specifically in vEDS"
  },
  "clinical_pearls": [
    "Celiprolol is the ONLY drug with RCT evidence in vEDS",
    "60% relative risk reduction in arterial events in the Ong trial",
    "Not FDA-approved in US - may require special access programs",
    "If celiprolol unavailable, use conventional beta-blockers"
  ],
  "semantic_relations": {
    "broader": ["aku:vascular:genetic:vascular-ehlers-danlos"],
    "narrower": [],
    "related": [
      "aku:vascular:genetic:eds-002-col3a1",
      "aku:vascular:genetic:eds-003-surgical-avoidance",
      "aku:pharmacology:beta-blockers"
    ],
    "prerequisites": ["aku:vascular:genetic:vascular-ehlers-danlos"]
  },
  "learning_objectives": [
    "Summarize the evidence from the celiprolol trial in vascular Ehlers-Danlos syndrome",
    "Describe the unique pharmacologic properties of celiprolol",
    "Apply celiprolol therapy in clinical management of vEDS"
  ],
  "relationships": {
    "prerequisites": [
      {
        "id": "aku:vascular:genetic:vascular-ehlers-danlos",
        "title": "Vascular Ehlers-Danlos Syndrome Overview",
        "strength": 1.0,
        "reason": "Must understand vEDS pathophysiology"
      }
    ],
    "enables": [],
    "related": [
      {
        "id": "aku:vascular:genetic:eds-003-surgical-avoidance",
        "type": "alternative_management",
        "relationship": "Medical management preferred over surgery"
      },
      {
        "id": "aku:vascular:genetic:marfan-005-beta-blocker",
        "type": "comparison",
        "relationship": "Similar concept of beta-blockade but different evidence base"
      }
    ]
  },
  "provenance": {
    "sources": [
      {
        "type": "randomized_controlled_trial",
        "citation": "Ong KT, et al. Effect of celiprolol on prevention of cardiovascular events in vascular Ehlers-Danlos syndrome. Lancet. 2010;376(9751):1476-1484",
        "confidence": 1.0,
        "level_of_evidence": "1b"
      }
    ],
    "extraction_method": "primary_literature_review"
  },
  "metadata": {
    "version": "1.0.0",
    "created": "2026-01-06T18:24:00.000Z",
    "updated": "2026-01-06T18:24:00.000Z",
    "contributors": ["copilot-agent", "knowledge-graph-agent"],
    "status": "validated",
    "confidence": 0.95
  }
}
